H1N1(新型インフルエンザA)ワクチンの世界市場2016-2020...市場調査レポートについてご紹介

【英文タイトル】Global H1N1 Vaccines Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Causes of H1N1 diseases
• Signs and symptoms

PART 06: Regulatory scenario of vaccines

PART 07: WHO recommendations for H1N1 vaccines
• Key H1N1 virus vaccines for 2014-2015 season in US
• H1N1 virus vaccines approved in EU

PART 08: Reimbursement for influenza vaccines in US
• The US healthcare reform
• Reimbursement for influenza vaccines

PART 09: Reimbursement for influenza vaccines in other major countries
• UK
• Germany
• Spain
• Italy
• France
• Japan

PART 10: Market landscape
• Global human vaccines market
• Global H1N1 vaccines market
• Five forces analysis

PART 11: Market segmentation by ROA
• Intramuscular vaccines
• Intranasal vaccines
• Intradermal vaccines

PART 12: Geographical segmentation
• Global H1N1 vaccines market by geographical segmentation 2015-2020
• H1N1 vaccines market in Americas
• H1N1 vaccines market in EMEA
• H1N1 vaccines market in APAC

PART 13: Market drivers
• Global action plan for influenza vaccines
• Increase in R&D
• Inclusion in NIP
• Rise in awareness

PART 14: Impact of drivers

PART 15: Market challenges
• Antigenic drift and shift of H1N1v virus
• Vaccine storage and handling issues
• Stringent regulatory guidelines
• Emergence of local players

PART 16: Impact of drivers and challenges

PART 17: Market trends
• Universal influenza vaccine
• Emergence of quadrivalent vaccines
• Increase in strategic alliances and M&A
• Improved understanding of immunology

PART 18: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• Sanofi
• GSK
• AstraZeneca
• CSL
• Other prominent vendors

PART 19: Appendix
• List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for H1N1 vaccines
Exhibit 03: Pediatric influenza vaccine price list 2015
Exhibit 04: Adult influenza vaccine price list 2015
Exhibit 05: Requirements for a BLA submission
Exhibit 06: Different types of development necessary to reach the vaccine licensing stage
Exhibit 07: Typical vaccine development process (over a period of up to 15 years and at a cost of up to $1 billion)
Exhibit 08: Regulatory testing of licensed vaccines
Exhibit 09: Comparison of US healthcare system before and after reforms
Exhibit 10: Coding options for diagnosis of influenza vaccines
Exhibit 11: Medicare (Part B) current procedural terminology (CPT) codes for influenza vaccines
Exhibit 12: Top 10 pharmaceutical companies based on global vaccines market revenues 2015 ($ billions)
Exhibit 13: Global human vaccines market 2015-2020 ($ billions)
Exhibit 14: Market share of H1N1 vaccines markets in global human vaccines market 2015
Exhibit 15: Global H1N1 vaccines market 2015-2020 ($ billions)
Exhibit 16: Five forces analysis
Exhibit 17: Global H1N1 vaccines market segmentation by ROA
Exhibit 18: Global H1N1 vaccines market segmentation by ROA 2015
Exhibit 19: Global H1N1 vaccines market by geography 2015
Exhibit 20: Global H1N1 vaccines market by geography 2020
Exhibit 21: Global H1N1 vaccines market revenue by geography 2015-2020 ($ billions)
Exhibit 22: Percentage share of H1N1 vaccines market by geography 2015-2020
Exhibit 23: Global H1N1 vaccines market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 24: H1N1 vaccines market in Americas 2015-2020 ($ billions)
Exhibit 25: H1N1 vaccines market in EMEA 2015-2020 ($ millions)
Exhibit 26: H1N1 vaccines market in APAC 2015-2020 ($ millions)
Exhibit 27: A few pipeline molecules for H1N1 vaccines
Exhibit 28: Impact of drivers
Exhibit 29: A typical cold chain process
Exhibit 30: Impact of drivers and challenges
Exhibit 31: Overview of major H1N1 vaccine-related acquisitions 2005-2012)
Exhibit 32: Market share analysis of global H1N1 vaccines market 2015
Exhibit 33: Sanofi: YoY revenue growth of influenza vaccines 2013-2015 ($ billions)
Exhibit 34: Sanofi: Geographic segmentation of influenza vaccines 2015
Exhibit 35: Sanofi: Key takeaways
Exhibit 36: GSK: YoY revenue and growth rate of Fluarix and FluLaval 2013-2015 ($ millions)
Exhibit 37: GSK: Geographical segmentation of Fluarix and FluLaval 2015
Exhibit 38: GSK: Key takeaways
Exhibit 39: AstraZeneca: YoY revenue and growth rate of Fluenz 2013-2015 ($ millions)
Exhibit 40: AstraZeneca: Geographical segmentation of Fluenz 2015 ($ millions)
Exhibit 41: AstraZeneca: Key takeaways
Exhibit 42: CSL: YoY revenue and growth rate of influenza vaccines 2013-2015 ($ millions)
Exhibit 43: CSL: Key takeaways


【レポート販売概要】

■ タイトル:H1N1(新型インフルエンザA)ワクチンの世界市場2016-2020
■ 英文:Global H1N1 Vaccines Market 2016-2020
■ 発行日:2016年6月3日
■ 調査会社:Technavio
■ 商品コード:IRTNTR9538
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。